We are live on ! Find out more
BLFS icon

BioLife Solutions

164 hedge funds and large institutions have $797M invested in BioLife Solutions in 2022 Q1 according to their latest regulatory filings, with 30 funds opening new positions, 72 increasing their positions, 43 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 43

0.38% more ownership

Funds ownership: 84.06%84.44% (+0.38%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

3% less funds holding

Funds holding: 169164 (-5)

12% less first-time investments, than exits

New positions opened: 30 | Existing positions closed: 34

39% less capital invested

Capital invested by funds: $1.31B → $797M (-$508M)

84% less call options, than puts

Call options by funds: $180K | Put options by funds: $1.12M

Holders
164
Holders Change
-5
Holders Change %
-2.96%
% of All Funds
2.59%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
30
Increased
72
Reduced
43
Closed
34
Calls
$180K
Puts
$1.12M
Net Calls
-$937K
Net Calls Change
+$1.55M
Name Holding Trade Value Shares
Change
Change in
Stake
CC
1
Casdin Capital
New York
$172M
BlackRock
2
BlackRock
New York
$84.4M +$1.52M +57,623 +2%
Vanguard Group
3
Vanguard Group
Pennsylvania
$50M +$1.43M +54,344 +3%
FAM
4
Fred Alger Management
New York
$42.1M +$4.11M +155,997 +9%
GCM
5
Geneva Capital Management
Wisconsin
$33.1M -$852K -32,348 -2%
RIM
6
Ranger Investment Management
Texas
$29.6M +$1.19M +45,147 +4%
Millennium Management
7
Millennium Management
New York
$24.4M +$14.1M +534,735 +99%
Ameriprise
8
Ameriprise
Minnesota
$24.4M -$78.2K -2,971 -0.3%
State Street
9
State Street
Massachusetts
$22.9M +$2.2M +83,511 +9%
Marshall Wace
10
Marshall Wace
United Kingdom
$20.1M -$12.1M -461,287 -34%
Invesco
11
Invesco
Georgia
$17.3M -$243K -9,247 -1%
GIM
12
Granahan Investment Management
Massachusetts
$13.9M +$4.61M +175,172 +40%
PCM
13
Palisade Capital Management
New Jersey
$12.5M -$1.01M -38,219 -6%
TCM
14
TimesSquare Capital Management
New York
$11M +$65.8K +2,500 +0.5%
N
15
Nuveen
North Carolina
$10.5M +$2.09M +79,434 +21%
Russell Investments Group
16
Russell Investments Group
United Kingdom
$10.3M -$1.56M -59,114 -12%
JP Morgan Chase
17
JP Morgan Chase
New York
$9.99M -$846K -32,123 -7%
Bank of America
18
Bank of America
North Carolina
$9.94M -$2.5M -94,903 -18%
Jennison Associates
19
Jennison Associates
New York
$9.6M -$10.9M -415,907 -50%
GS
20
Gagnon Securities
New York
$8.63M +$1.65M +62,537 +20%
ZDA
21
Zweig-DiMenna Associates
New York
$8.56M +$1.57M +59,567 +19%
Geode Capital Management
22
Geode Capital Management
Massachusetts
$8.3M -$217K -8,261 -2%
CRC
23
Curi RMB Capital
Illinois
$7.39M +$1.02M +38,643 +13%
PCM
24
Peregrine Capital Management
Minnesota
$7.07M -$586K -22,277 -7%
Fidelity Investments
25
Fidelity Investments
Massachusetts
$6.72M -$2.49M -94,604 -24%

BLFS Hedge Fund Activity: Q1 2022 in Review

164 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in BioLife Solutions (BLFS) for Q1 2022, worth a combined $797M — down 39% from $1.31B a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of BLFS and 30 opened new positions — a net loss of 4 holders — while 43 trimmed existing stakes and 72 added.

The largest buyer was Millennium Management, adding an estimated $14.1M. The largest seller was Marshall Wace, cutting an estimated $12.1M.

  • 164 institutional investors held BioLife Solutions (BLFS) as of Q1 2022, down from 169 in Q4 2021.
  • Funds reported $797M of BioLife Solutions stock for Q1 2022, down 39% quarter-over-quarter.
  • 30 funds opened new BioLife Solutions positions in Q1 2022 and 34 closed out, a net change of -4 holders.
  • The largest BioLife Solutions buyer in Q1 2022 was Millennium Management, an estimated $14.1M added.
  • The largest BioLife Solutions seller in Q1 2022 was Marshall Wace, an estimated $12.1M sold.

Based on aggregated 13F filings for Q1 2022.